1. Medtech Insight
  2. >>Leadership

AdvaMed Throws Weight Behind Protestors In Ongoing US Demonstrations

The move is unusual for a group that tends to stay out of the political fray

AdvaMed CEO Scott Whitaker shared a letter he sent to member companies voicing support for the ongoing protests around the US against police brutality that were sparked after the killing of George Floyd. “While we continue our single-minded pursuit of medical breakthroughs to treat and cure disease, we must also have a single-minded focus on eradicating the disease of racism in this country and around the world,” Whitaker wrote.

comments made by Scott Whitaker (left) and Kevin Lobo (right)
ADVAMED CEO SCOTT WHITAKER (LEFT) AND CHAIRMAN KEVIN LOBO AT THE 2019 MEDTECH CONFERENCE IN BOSTON • Source: Ferdous Al-Faruque

For an organization that tends to stay out of the political fray, the medtech lobby group AdvaMed took the unusual step of voicing support for protesters who’ve been carrying out nationwide demonstrations calling for law enforcement reforms after a black man was killed by a police officer in Minneapolis, MN.

AdvaMed CEO Scott Whitaker on 3 June published a letter on LinkedIn that was sent to all the group’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

NIH-Backed Scanner Opens New Frontier For Understanding The Human Brain

 
• By Brian Bossetta

A new MRI scanner developed by a team of scientists working with the National Institutes of Health marks a milestone in understanding the complexities of the human brain. Andrea Beckel-Mitchener with the NIH Brain Initiative discusses the significance of this potentially game-changing device.

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 
• By Natasha Barrow

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.

Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman

 
• By Natasha Barrow

Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.

From ‘Work Harder’ to ‘Phenomenal People’: Makary’s FDA About-Face

 
• By Michael McCaughan

In his first 100 days as FDA commissioner, Martin Makary has gone from vocal critic to vocal supporter of the agency’s staff, calling them “phenomenal” and praising their dedication—even as morale remains shaken by recent layoffs and restructuring.

More from Medtech Insight

Olympus, Revival Co-Found Swan In $458M Deal, Face Tech and Regulatory Hurdles

 
• By Marion Webb

Olympus and Revival Healthcare Capital have launched Swan Endosurgical in a $458m milestone-based joint venture to develop a robotic platform for endoluminal surgery. The deal combines Olympus’ GI expertise with Revival’s start-up model, but will face technical and regulatory hurdles.

Alternative Funding Sources Emerge Amid Biotech Industry Challenges

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 
• By Natasha Barrow

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.